Database Query Results : , , CD11b

CD11b, CD11b: Click to Expand ⟱

Source:

Type:

CD11b’s (also known as integrin αM or ITGAM).
Markers CD14 and CD11b is one of the important characteristics of differentiation.

High levels of CD11b are often noted in the tumor microenvironment.
A high density of CD11b⁺ cells in the tumor microenvironment has been associated with adverse prognosis. For example, an abundance of MDSCs (which are CD11b⁺) is linked to immunosuppression, tumor progression, and resistance to therapies. High levels of CD11b⁺ cell infiltration have been correlated with:
-Faster tumor progression.
-Increased metastasis.
-Reduced response to immunotherapies.

Scientific Papers found: Click to Expand⟱

4936-

PEITC,

PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth

in-vivo,

BC,

MDA-MB-231

Breast tumors are heterogeneous with a complex etiology. The immune system plays a crucial role in the development of tumors and can facilitate tumor growth pleiotropically. Myeloid derived suppressor cells (MDSCs) generate reactive oxygen species (ROS) and cytokines to suppress T cells, dendritic cells and natural killer (NK) cells. Hence, the inhibition of MDSCs could be an important strategy for anticancer therapeutics. Phenethyl isothiocyanate (PEITC), a bioactive compound present in cruciferous vegetables, is known to have anticancer properties. However, the effects of PEITC administration on the immune system have not been previously reported. In the current study, we evaluated the effects of administering PEITC to immunocompromised NOD-SCID IL2Rγ−/− (SCID/NSG) host mice bearing MDA-MB-231 xenografts on MDSCs in the peripheral blood. Our results reveal that oral administration of 12 μmol PEITC attenuated tumor growth by 76%. This was marked tumor-inhibitory phenotype was associated with a significant reduction in the levels of MDSCs bearing the surface markers CD33, CD34 and <span class="wphighlight">CD11b</span> in PEITC treated mice, indicating that overall tumor growth suppression by PEITC correlates with inhibition of MDSCs. To the best of our knowledge, this is the first study showing effects of PEITC on MDSCs.

TumCG↓, CD34↓, CD11b↓, CSCs↓, ALC∅, CD4+↓, NF-kB↓, STAT3↓, Hif1a↓,

1345-

SK,

The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway

in-vitro,

AML,

HL-60

100 ng/mL

CD14↑, CD11b↑, ROS↑, GSH↓, GSH/GSSG↓, GPx↑, Catalase↓, Diff↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Clinical Biomarkers ⓘ

ALC∅, 1,
Total Targets: 17

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: CD11b, CD11b

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1067  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Database Query Results : , , CD11b

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Immune & Inflammatory Signaling ⓘ

Clinical Biomarkers ⓘ

Pathway results for Effect on Normal Cells:

Home Page